Vancouver, Canada — Anavex Life Sciences Corp. (“Anavex”) announced on July 9 that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease currently in human clinical trials, will be presented in a poster session at the 2012 Alzheimer’s Association International Conference (AAIC) in Vancouver, BC, Canada.

The ANAVEX 2-73 poster will be presented by Tangui Maurice, PhD, CNRS Research Director, Team II Endogenous Neuroprotection in Neurodegenerative Diseases INSERM, University of Montpellier. The presentation will be held on Monday, July 16 from 1 PM- 3:30 PM. The title of the presentation will be: ”Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer’s disease: Analyses of administration schedules and combination studies with donepezil and memantine.”

AAIC 2012 takes place Saturday, July 14 to Thursday, July 19, 2012 in Vancouver. It is the world’s premiere forum for reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer’s disease and related disorders. The conference website boasts that AAIC 2012 will “join the world’s leading dementia scientists to share the latest thoughts and theories in the field – and spark new ideas along the way.” Additional information about the conference is available at http://www.alz.org/aaic/.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug candidates. Anavex utilizes its proprietary SIGMACEPTOR Platform to develop drug candidates targeting specific clinical indications. Lead compound ANAVEX 2-73, developed to treat Alzheimer’s through disease modification, is in human clinical trials.

A Phase 1 single ascending dose study of ANAVEX 2-73 was successfully completed in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties, and that it is well tolerated in doses up to 55mg. The company is preparing to embark on a multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex is a publicly traded corporation quoted as AVXL.

Image Courtesy of   Argonne National Laboratory

The article New Alzheimer’s Drug Shows Promise appeared first on The Toonari Post - News, Powered by the People!.

Orlando, U.S.A. — A cross-disciplinary team of international researchers gathered in Orlando, July 6-7 to present emerging research on the role glucose transporters and glucose metabolism may have in the management of chronic health conditions such as diabetes, cancer treatment, heart disease, epilepsy Glut1 Deficiency Syndrome and Alzheimer’s. The conference represents the first time researchers and healthcare professionals from different specialties have gathered to present research on the topic.

The organization of the conference is all in a day’s work for the mother of two, Samra Savioz. In 2010, she worked with her husband to start a foundation, the Remi Savioz Glut1 Foundation, aimed at raising awareness for their daughter Remi’s rare neurometabolic brain disease, Glut1 Deficiency.

But with many cases still going undiagnosed because of the lack of information available and the rarity of their daughter’s condition, the Savioz’s started to leverage their own medical backgrounds to help others impacted by the disease.

The Foundation has become a valued asset for parents needing support and guidance on treatment options, like the ketogenic diet, which has been identified as an integral part of disease treatment. Now, Samra provides one-on-one diet training and hopes to expand the understanding of how ketones can impact other diseases.

Sponsored by the Remi Savioz Glut1 Foundation, The Glucose Transporter Conference brought together several medical disciplines including pediatrics, neuro-oncology and endocrinology.

Eighteen abstracts were presented on the role of glucose transporters:

Topics for the conference included:

• The link between glucose starvation in shrinking cancerous tumors or slowing down the progression of cognitive diseases.
• Insights into the structural basis of Glut1 transporters in the brain to expand the clinical spectrum.
• Alternative therapies like ketone esters, which can have broader applications, like restoring cognitive function to Alzheimer’s patients or preventing seizures.
• Applying knowledge about glucose metabolism in the brain for obesity and diabetes treatment.
• Among the highlights of the research will be exploring the role of ketone esters.

“The conference will provide an important platform for us to share research focused on exploiting the anti-seizure and neuroprotective effects of therapeutic ketosis. Ketone esters may offer great hope for patients with drug-resistant seizure disorders and neurodegenerative diseases,” stated Dr. Dominic D’Agostino, Ph.D., Professor of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida before the conference. “Our recent studies have demonstrated that specific ketone esters mimic the anti-seizure effect of fasting and the ketogenic diet.”

Glut1 is a glucose transporter protein, which is directly or indirectly involved in a host of diseases, including cancer and diabetes. Novel therapeutic agents aimed at altering glucose transport activity may have a broad impact on human health. There are four types of glucose transporters with Glut1 being responsible for moving glucose from the bloodstream into all of the cells in the body, especially the brain.

The article Researchers Explore Importance of Glucose Transporters appeared first on The Toonari Post - News, Powered by the People!.

Washington, U.S.A. – The Geoffrey Beene Gives Back Alzheimer’s Initiative announced June 19 Team Ginger.io, of Cambridge, Massachusetts, as the winner of the Alzheimer’s Challenge 2012. The winning team, selected June 19 during an event in Washington, D.C., was awarded $175,000 to help further develop their idea for a behavioral analytics platform using a combination of a mobile phone application and web-based dashboard. The Alzheimer’s Immunotherapy Program (AIP) of Janssen Alzheimer Immunotherapy and Pfizer Inc. sponsored and provided program support and funding for the Alzheimer’s Challenge 2012.

The winning solution, announced by George Vradenburg, Chairman of GBGBAI, founder of the US Against Alzheimer’s Network and a member of the National Alzheimer’s Advisory Council, is an application that links ongoing monitoring of Alzheimer’s patients’ behavior relevant to their mood, memory, and functional status to health care professionals who are also provided with an integrated dashboard of diagnostic tools and treatment options to streamline therapeutic response time. Patients also get a digital window into their own brain health.

Five finalist teams, selected from over 100 submissions, presented a prototype of their idea to a panel of esteemed judges during the finalist event led by InnoCentive, the open innovation and crowd-sourcing pioneer that assisted with development of the judging criteria.

“A disease as complex and pervasive as Alzheimer’s demands multiple therapeutic solutions from a diversity of new perspectives,” said Tom Hutton, Trustee of the Geoffrey Beene Foundation and President and Chief Executive Officer of Geoffrey Beene, LLC. “That is why we are committed to supporting today’s winners and finalists as well as the next round of open source competitions under Geoffrey Beene’s Rock Stars of Science Global Grand Challenge.  This is innovation the way it should be: open, fast, and focused on the issues that matter most.”

Vradenburg, a close ally in GBGBAI’s ongoing commitment to innovation in Alzheimer’s research, sees the winning and finalist solutions as part of a turning point in the fight against Alzheimer’s:

“Technology-driven innovations are a critical tool in detecting and monitoring Alzheimer’s progression. ‘Business-as-usual’ is a death sentence for the 10 million Baby Boomers who now have or are at risk for this disease. The winners and finalists of the Alzheimer’s Challenge 2012 are the leading edge of the new high-tech weapons we need to defeat this disease by 2025. We are deeply grateful to all our finalists for forging new paths forward in the fight against Alzheimer’s.”

“We are honored to win the Alzheimer’s Challenge 2012 and help bring a new tool to the Alzheimer’s community that uses technology in a creative and effective way to help advance patient care,” said Sai Moturu, Ph.D., the Ginger.io team lead. “We are eager to take our concept to the next level of development and are grateful for the support we’ve received through the Challenge.”

All finalist teams, from which the winner was chosen, were awarded $25,000 in development prizes for such innovation solutions as:

Team ClockSketch of Burlington, Massachusetts submitted The Digital Clock Drawing Test (dCDT). The latest virtual rendering ‘digital ink” technology extends a widely used diagnostic clock drawing test for mild cognitive impairment to more sensitively detect subtle and previously unmeasurable changes in behavior, then converts each patient’s data into a universally sharable database.

Team ICHANGE of Portland, Oregon submitted ICHANGE or Intelligent Continuous Health Assessment with Noninvasive Gerotechnology. It seeks to transform the way we identify dementia by changing how and where we assess for change, from a brief unnatural snapshot of time in a clinic setting to a real-world, real-time view of a person’s entire function in their home. The ICHANGE system continuously and coincidently monitors signature activities and behaviors of those with Alzheimer’s disease that are readily assessed without the need to remember to wear or charge a device. An array of inexpensive sensors is used to unobtrusively measure key functions whose change has been associated with the progression of cognitive decline. Data are then aggregated and analyzed with prediction algorithms that are then streamed to stakeholders of interest (caregiver, doctor, clinical trialists), providing real-time reports of meaningful change.

Team BrainBaseline of Iowa City, Iowa submitted BrainBaseline, a convenient iPad-based time measurement of a patient’s memory, attention, language and other cognitive processes that automatically cross-references with the patient’s lifestyle to update family and caregivers, recommend ways to improve quality of life, and also track the effect of lifestyle factors on Alzheimer’s progression for larger demographic studies.

Team VF-Meter of Minneapolis, Minnesota submitted The Verbal Fluency Meter (VF-Meter), a brief, non-invasive computerized instrument that measures and monitors over time subtle cognitive changes specific to Alzheimer’s disease. The instrument automates the administration and results analysis of a standard verbal fluency task using a variety of commonly used communication interfaces including telephones, computers and mobile devices. The automated measurements will then be used to evaluate individual current cognitive state, monitor cognitive change over time and predict the relative likelihood and rate of disease progression.

Building on the success of the Alzheimer’s Challenge 2012, GBGBAI is soon set to launch the Geoffrey Beene’s Rock Stars of Science Global Grand Challenge, the second in its series of prize-based challenge competitions designed in coordination with InnoCentive, which is aimed at accelerating clinical trials and mining data to uncover risk factors in presymptomatic populations. Winning solutions will be announced in early 2013.

The article Alzheimer’s Challenge Winners Receive $300,000 in Prizes appeared first on The Toonari Post - News, Powered by the People!.